Lupin Strengthens Diabetes Portfolio with Huminsulin Acquisition from Lilly

Lupin Ltd announced that it has acquired the anti-diabetic medicine 'Huminsulin' in India from Eli Lilly and Company for an undisclosed amount. Lupin has already been marketing the 'Huminsulin' products under existing agreements with Lilly, the company stated in a regulatory filing.

This move aims to strengthen Lupin's diabetes portfolio.Lupin has been marketing the Huminsulin range, including Huminsulin R, NPH, 50/50, and 30/70, through agreements with Lilly in India.

The Huminsulin products are essential for managing type 1 and type 2 diabetes by controlling blood sugar in adults and children. While insulin is vital for type 1 diabetes, it also becomes crucial for type 2 diabetes as the condition progresses.

Read more - Himanshu Ratnoo Steps Up as CEO of CARS24 Used Cars India

Rajeev Sibal, President , India Region Formulations, Lupin, said, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”

Nilesh Gupta, Managing Director, Lupin, said, “This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care.”

The Huminsulin products are used to treat Type 1 and Type 2 diabetes, helping to control blood sugar in both adults and children. Insulin is key in managing Type 1 diabetes and often becomes necessary for Type 2 diabetes as the disease progresses, the company said.

About Lupin

Lupin Limited is a global pharmaceutical company based in Mumbai, India, with products available in over 100 markets. The company focuses on branded and generic medications, complex generics, biotechnology products, and active pharmaceutical ingredients.

Lupin has 15 advanced manufacturing sites and 7 research centers worldwide, supported by a team of over 22,000 employees. The company is dedicated to improving patient health through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Funding News: Your Gateway to Every Funding Update.

Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges and achieving success.